springworks
therapeutics
announces
clinical
collaboration
pfizer
evaluate
nirogacestat
combination
patients
relapsed
refractory
multiple
myeloma
stamford
globe
newswire
springworks
therapeutics
nasdaq
swtx
biopharmaceutical
company
focused
developing
medicines
patients
severe
rare
diseases
cancer
today
announced
company
entered
clinical
trial
collaboration
agreement
pfizer
nyse
pfe
evaluate
springworks
therapeutics
investigational
gamma
secretase
inhibitor
gsi
nirogacestat
combination
pfizer
maturation
antigen
bcma
bispecific
antibody
patients
relapsed
refractory
multiple
myeloma
gamma
secretase
inhibition
prevents
cleavage
shedding
bcma
surface
myeloma
cells
preclinical
models
nirogacestat
shown
increase
cell
surface
density
bcma
reduce
levels
soluble
bcma
thereby
enhancing
activity
therapies
including
bispecific
antibodies
collaboration
another
important
step
continuing
advance
goal
developing
nirogacestat
bcma
potentiator
pleased
work
pfizer
study
nirogacestat
combination
recently
demonstrated
promising
monotherapy
clinical
data
said
saqib
islam
chief
executive
officer
springworks
therapeutics
five
collaborations
bcma
developers
evaluate
nirogacestat
combinations
across
modalities
look
forward
generating
clinical
data
collaborators
evaluate
ability
nirogacestat
improve
outcomes
patients
multiple
terms
agreement
pfizer
sponsor
conduct
phase
study
evaluate
safety
tolerability
preliminary
efficacy
combination
assume
costs
associated
study
expenses
related
manufacturing
nirogacestat
certain
expenses
related
intellectual
property
rights
pfizer
springworks
therapeutics
also
form
joint
development
committee
manage
clinical
study
expected
commence
first
half
entering
clinical
collaboration
proud
milestone
strong
relationship
springworks
said
chris
boshoff
md
phd
chief
development
officer
pfizer
oncology
pfizer
believe
studying
nirogacestat
combination
could
hold
significant
therapeutic
promise
patients
relapsed
refractory
multiple
myeloma
look
forward
working
together
advance
important
area
addition
ongoing
clinical
collaborations
therapies
springworks
also
currently
conducting
global
phase
randomized
clinical
trial
defi
trial
evaluate
nirogacestat
adults
progressing
desmoid
tumors
nirogacestat
nirogacestat
investigational
oral
selective
small
molecule
gamma
secretase
inhibitor
phase
clinical
development
desmoid
tumors
rare
often
debilitating
disfiguring
tumors
gamma
secretase
cleaves
multiple
transmembrane
protein
complexes
including
notch
believed
play
role
activating
pathways
contribute
desmoid
tumor
growth
addition
gamma
secretase
shown
directly
cleave
bcma
resulting
release
bcma
extracellular
domain
ecd
cell
surface
inhibiting
gamma
secretase
bcma
preserved
increasing
target
density
reducing
levels
soluble
bcma
ecd
may
serve
decoy
receptors
therapies
nirogacestat
ability
enhance
activity
therapies
observed
preclinical
models
multiple
myeloma
springworks
evaluating
nirogacestat
bcma
potentiator
five
collaborations
bcma
developers
evaluate
nirogacestat
combinations
across
modalities
including
conjugate
two
car
cell
therapies
two
bispecific
antibodies
addition
springworks
fred
hutchinson
cancer
research
center
entered
sponsored
research
agreement
characterize
ability
nirogacestat
modulate
bcma
potentiate
bcma
directed
therapies
using
variety
preclinical
multiple
myeloma
models
developed
researchers
fred
hutch
nirogacestat
received
orphan
drug
designation
food
drug
administration
fda
treatment
desmoid
tumors
june
european
commission
treatment
soft
tissue
sarcoma
september
fda
also
granted
fast
track
breakthrough
therapy
designations
treatment
adult
patients
progressive
unresectable
recurrent
refractory
desmoid
tumors
deep
fibromatosis
november
august
maturation
antigen
bcma
bispecific
antibody
investigated
phase
clinical
study
treat
relapsed
refractory
multiple
myeloma
bispecific
antibody
administered
subcutaneously
optimized
binding
affinity
bcma
enabling
potent
tumor
cell
toxicity
springworks
therapeutics
springworks
biopharmaceutical
company
applying
precision
medicine
approach
acquiring
developing
commercializing
medicines
underserved
patient
populations
suffering
devastating
rare
diseases
cancer
springworks
differentiated
portfolio
small
molecule
targeted
oncology
product
candidates
advancing
two
potentially
registrational
clinical
trials
rare
tumor
types
well
several
programs
addressing
highly
prevalent
genetically
defined
cancers
springworks
strategic
approach
operational
excellence
clinical
development
enabled
rapidly
advance
two
lead
product
candidates
clinical
trials
simultaneously
entering
multiple
partnerships
industry
leaders
expand
portfolio
information
visit
follow
springworkstx
twitter
linkedin
springworks
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
statements
regarding
springworks
clinical
trials
strategy
business
plans
focus
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
related
springworks
financial
results
timing
initiation
completion
springworks
clinical
trials
product
candidates
whether
springworks
product
candidates
receive
approval
food
drug
administration
fda
foreign
regulatory
authorities
uncertainties
assumptions
regarding
impact
pandemic
springworks
business
operations
clinical
trials
supply
chain
strategy
goals
anticipated
timelines
competition
biopharmaceutical
companies
risks
identified
section
entitled
risk
factors
item
part
ii
springworks
quarterly
report
form
quarter
ended
june
well
discussions
potential
risks
uncertainties
important
factors
springworks
subsequent
filings
securities
exchange
commission
springworks
cautions
place
undue
reliance
statements
speak
date
made
springworks
disclaims
obligation
publicly
update
revise
statements
reflect
change
expectations
events
conditions
circumstances
statements
may
based
may
affect
likelihood
actual
results
differ
set
forth
statements
statements
contained
press
release
represent
springworks
views
date
hereof
relied
upon
representing
views
subsequent
date
